4507 Stock Overview
Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Shionogi & Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥7,129.00 |
| 52 Week High | JP¥8,137.00 |
| 52 Week Low | JP¥5,718.00 |
| Beta | 0.38 |
| 1 Month Change | 0.21% |
| 3 Month Change | -0.084% |
| 1 Year Change | 14.23% |
| 3 Year Change | 22.72% |
| 5 Year Change | 14.69% |
| Change since IPO | 655.99% |
Recent News & Updates
Shareholder Returns
| 4507 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -4.8% | -0.08% | 0.4% |
| 1Y | 14.2% | 4.3% | 24.2% |
Return vs Industry: 4507 exceeded the JP Pharmaceuticals industry which returned 4.3% over the past year.
Return vs Market: 4507 underperformed the JP Market which returned 24.2% over the past year.
Price Volatility
| 4507 volatility | |
|---|---|
| 4507 Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.0% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4507 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4507's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1878 | 4,959 | Isao Teshirogi | www.shionogi.com |
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19.
Shionogi & Co., Ltd. Fundamentals Summary
| 4507 fundamental statistics | |
|---|---|
| Market cap | JP¥2.02t |
| Earnings (TTM) | JP¥162.03b |
| Revenue (TTM) | JP¥435.08b |
12.5x
P/E Ratio4.6x
P/S RatioIs 4507 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4507 income statement (TTM) | |
|---|---|
| Revenue | JP¥435.08b |
| Cost of Revenue | JP¥57.60b |
| Gross Profit | JP¥377.48b |
| Other Expenses | JP¥215.45b |
| Earnings | JP¥162.03b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 571.55 |
| Gross Margin | 86.76% |
| Net Profit Margin | 37.24% |
| Debt/Equity Ratio | 0% |
How did 4507 perform over the long term?
See historical performance and comparison